Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.

Date publication

juillet 2022

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse

Tous les auteurs :
Nagler A, Galimard JE, Labopin M, Blaise D, Arcese W, Trisolini SM, Wu D, Pigneux A, Van Gorkom G, Rubio MT, Gedde-Dahl T, Huynh A, Lanza F, Gorin NC, Mohty M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35891608

Résumé

Achieving complete remission (CR) is the main goal in AML treatment and a prerequisite for successful autologous stem cell transplantation (ACT).

Mots clés

acute myeloid leukemia, autologous, complete remission, induction chemotherapy, stem cell transplantation

Référence

Cancer Med. 2022 07 26;: